Using a mouse and human model of bladder cancer, we demonstrated that the combined use of local HDACi and systemic anti-PD-1 was effective at inducing curative CD8 T cell immune responses against primary lesions with durable anti-tumor immunity against a secondary and distal tumor. Here, CD8A is linked to urinary bladder carcinoma.